-+ 0.00%
-+ 0.00%
-+ 0.00%

Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $94

Benzinga·02/06/2026 12:51:16
Listen to the news
Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $93 to $94.